

Rosario Pivonello

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7004413/publications.pdf>

Version: 2024-02-01

214
papers

13,466
citations

12330

69
h-index

27406

106
g-index

224
all docs

224
docs citations

224
times ranked

8592
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term high-dose l-arginine supplementation in patients with vasculogenic erectile dysfunction: a multicentre, double-blind, randomized, placebo-controlled clinical trial. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 941-961.	3.3	6
2	Bone metabolism in patients with type 1 neurofibromatosis: key role of sun exposure and physical activity. <i>Scientific Reports</i> , 2022, 12, 4368.	3.3	6
3	The role of melatonin in the molecular mechanisms underlying metaflammation and infections in obesity: A narrative review. <i>Obesity Reviews</i> , 2022, 23, e13390.	6.5	18
4	The dopaminergic control of Cushing's syndrome. <i>Journal of Endocrinological Investigation</i> , 2022, , 1.	3.3	5
5	Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 874091.	2.8	2
6	Andrological effects of SARS-Cov-2 infection: a systematic review and meta-analysis. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 2207-2219.	3.3	37
7	Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence – Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 385-387.	11.4	4
8	Glucocorticoid excess and COVID-19 disease. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 703-714.	5.7	36
9	Sex Disparities in COVID-19 Severity and Outcome: Are Men Weaker or Women Stronger?. <i>Neuroendocrinology</i> , 2021, 111, 1066-1085.	2.5	85
10	Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing's syndrome. <i>Pituitary</i> , 2021, 24, 104-115.	2.9	20
11	Etiology-, Sex-, and Tumor Size-Based Differences in Adrenocorticotropin-Dependent Cushing Syndrome. <i>Endocrine Practice</i> , 2021, 27, 471-477.	2.1	5
12	Remission in Cushing's disease is predicted by cortisol burden and its withdrawal following pituitary surgery. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 1869-1878.	3.3	6
13	Diabetes is most important cause for mortality in COVID-19 hospitalized patients: Systematic review and meta-analysis. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 275-296.	5.7	152
14	Sperm Global DNA Methylation (SGDM) in Semen of Healthy Dogs. <i>Veterinary Sciences</i> , 2021, 8, 50.	1.7	2
15	Levoketoconazole in the Treatment of Patients With Cushing's Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study. <i>Frontiers in Endocrinology</i> , 2021, 12, 595894.	3.5	15
16	Metabolic syndrome in the era of COVID-19 outbreak: impact of lockdown on cardiometabolic health. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 2845-2847.	3.3	21
17	How May Obesity-Induced Oxidative Stress Affect the Outcome of COVID-19 Vaccines? Lesson Learned from the Infection. <i>Stresses</i> , 2021, 1, 119-122.	4.8	3
18	Levoketoconazole: a novel treatment for endogenous Cushing's syndrome. <i>Expert Review of Endocrinology and Metabolism</i> , 2021, 16, 159-174.	2.4	8

#	ARTICLE	IF	CITATIONS
19	Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study. <i>Frontiers in Endocrinology</i> , 2021, 12, 662865.	3.5	29
20	When to Suspect Hidden Hypercortisolism in Type 2 Diabetes: A Meta-Analysis. <i>Endocrine Practice</i> , 2021, 27, 1216-1224.	2.1	8
21	Hyperprolactinemia after menopause: Diagnosis and management. <i>Maturitas</i> , 2021, 151, 36-40.	2.4	4
22	Consensus on diagnosis and management of Cushing's disease: a guideline update. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 847-875.	11.4	315
23	Subclinical male hypogonadism. <i>Minerva Endocrinology</i> , 2021, 46, 252-261.	1.1	9
24	A New Clinical Model to Estimate the Pre-Test Probability of Cushing's Syndrome: The Cushing Score. <i>Frontiers in Endocrinology</i> , 2021, 12, 747549.	3.5	13
25	Risk Factors Affecting Puberty: Environment, Obesity, and Lifestyles. <i>Trends in Andrology and Sexual Medicine</i> , 2021, , 171-200.	0.1	0
26	Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms. <i>Frontiers in Endocrinology</i> , 2021, 12, 791633.	3.5	6
27	The treatment with pasireotide in Cushing's disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 57-73.	3.3	13
28	Pasireotide treatment significantly reduces tumor volume in patients with Cushing's disease: results from a Phase 3 study. <i>Pituitary</i> , 2020, 23, 203-211.	2.9	17
29	Male and female sexual dysfunction in diabetic subjects: Focus on new antihyperglycemic drugs. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 21, 57-65.	5.7	24
30	Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials. <i>Frontiers in Endocrinology</i> , 2020, 11, 648.	3.5	72
31	Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 748-761.	11.4	114
32	MON-332 Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome (LOGICS): A Double-Blind, Placebo-Controlled, Withdrawal Study. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.2	3
33	Use of glucocorticoids in patients with adrenal insufficiency and COVID-19 infection. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 472-473.	11.4	48
34	Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results from a phase III study. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1613-1622.	3.3	16
35	SARS-CoV-2 infection, male fertility and sperm cryopreservation: a position statement of the Italian Society of Andrology and Sexual Medicine (SIAMS) (Societ� Italiana di Andrologia e Medicina della) Tj ETQq1 1 0.7843 14 rgB39/Overlock	2.4	1
36	COVID-19 and Cushing's syndrome: recommendations for a special population with endogenous glucocorticoid excess. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 654-656.	11.4	23

#	ARTICLE	IF	CITATIONS
37	Vitamin D-Induced Molecular Mechanisms to Potentiate Cancer Therapy and to Reverse Drug-Resistance in Cancer Cells. <i>Nutrients</i> , 2020, 12, 1798.	4.1	69
38	Bisphenol A: an emerging threat to female fertility. <i>Reproductive Biology and Endocrinology</i> , 2020, 18, 22.	3.3	139
39	Erectile dysfunction and cardiovascular risk: a review of current findings. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 155-164.	1.5	33
40	Smoke, alcohol and drug addiction and female fertility. <i>Reproductive Biology and Endocrinology</i> , 2020, 18, 21.	3.3	69
41	Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma. <i>Cancers</i> , 2020, 12, 740.	3.7	28
42	COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1141-1147.	3.3	103
43	Imbalanced cortisol concentrations in glycogen storage disease type I: evidence for a possible link between endocrine regulation and metabolic derangement. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 99.	2.7	13
44	People smoke for nicotine, but lose sexual and reproductive health for tar: a narrative review on the effect of cigarette smoking on male sexuality and reproduction. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1391-1408.	3.3	36
45	ACTH increment post total bilateral adrenalectomy for Cushing's disease: a consistent biosignature for predicting Nelson's syndrome. <i>Pituitary</i> , 2020, 23, 488-497.	2.9	12
46	Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease. <i>European Journal of Endocrinology</i> , 2020, 182, 207-217.	3.7	29
47	Osteoporosis: May Doping Cause It?. <i>Trends in Andrology and Sexual Medicine</i> , 2020, , 163-173.	0.1	0
48	Advances in the medical treatment of Cushing's syndrome. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 300-312.	11.4	95
49	Pituitary Adenomas: What Are the Key Features? What Are the Current Treatments? Where Is the Future Taking Us?. <i>World Neurosurgery</i> , 2019, 127, 695-709.	1.3	16
50	Acromegaly and Heart Failure. <i>Heart Failure Clinics</i> , 2019, 15, 399-408.	2.1	20
51	Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR-375/oncogenes circuit. <i>Scientific Reports</i> , 2019, 9, 11695.	3.3	14
52	Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 855-865.	11.4	60
53	Risk behaviours and alcohol in adolescence are negatively associated with testicular volume: results from the AmicoAndrologo survey. <i>Andrology</i> , 2019, 7, 769-777.	3.5	34
54	Acromegaly. <i>Nature Reviews Disease Primers</i> , 2019, 5, 20.	30.5	247

#	ARTICLE	IF	CITATIONS
55	Dopamine Agonists: From the 1970s to Today. <i>Neuroendocrinology</i> , 2019, 109, 34-41.	2.5	24
56	The medical treatment with pasireotide in Cushing's disease: an Italian multicentre experience based on a real-world evidence. <i>Endocrine</i> , 2019, 64, 657-672.	2.3	33
57	OR16-2 Osilodrostat Treatment in Cushing's Disease (CD): Results from a Phase III, Multicenter, Double-Blind, Randomized Withdrawal Study (LINC 3). <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	3
58	SUN-463 Tumor Shrinkage with Preoperative Relacorilant Therapy in Two Patients with Cushing Disease Due to Pituitary Macroadenomas. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	7
59	Long-Term Complications of Hypercortisolism. , 2019, , 341-359.		1
60	SAT-452 Results from the Phase 3 Multicenter SONICS Study of Levoketoconazole: Subgroup Analysis of Cushing's Syndrome (CS) Patients with Diabetes Mellitus (DM). <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	1
61	Physiopathology, Diagnosis, and Treatment of Hypercortisolism. <i>Endocrinology</i> , 2018, , 325-374.	0.1	1
62	Pasireotide treatment reduces cardiometabolic risk in Cushing's disease patients: an Italian, multicenter study. <i>Endocrine</i> , 2018, 61, 118-124.	2.3	16
63	Physiopathology, Diagnosis, and Treatment of Hypercortisolism. <i>Endocrinology</i> , 2018, , 1-50.	0.1	0
64	Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 17-26.	11.4	116
65	Long-term safety of long-acting octreotide in patients with diabetic retinopathy: results of pooled data from 2 randomized, double-blind, placebo-controlled phase 3 studies. <i>Endocrine</i> , 2018, 60, 65-72.	2.3	6
66	Air pollution and female fertility: a systematic review of literature. <i>Reproductive Biology and Endocrinology</i> , 2018, 16, 117.	3.3	110
67	Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting. <i>Endocrine</i> , 2018, 62, 663-680.	2.3	9
68	Recombinant FSH Improves Sperm DNA Damage in Male Infertility: A Phase II Clinical Trial. <i>Frontiers in Endocrinology</i> , 2018, 9, 383.	3.5	21
69	ACTH-Secreting Pituitary Tumors. , 2018, , 248-260.		0
70	Smoke, alcohol and drug addiction and male fertility. <i>Reproductive Biology and Endocrinology</i> , 2018, 16, 3.	3.3	161
71	Germline polymorphisms of the VEGF-pathway predict recurrence in non-advanced differentiated thyroid cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, jc.2016-2555.	3.6	23
72	The degree of urinary hypercortisolism is not correlated with the severity of Cushing's syndrome. <i>Endocrine</i> , 2017, 55, 564-572.	2.3	32

#	ARTICLE	IF	CITATIONS
73	Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. <i>Endocrine</i> , 2017, 55, 872-884.	2.3	36
74	Cushing's disease: the burden of illness. <i>Endocrine</i> , 2017, 56, 10-18.	2.3	136
75	Shedding new light on female fertility: The role of vitamin D. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017, 18, 273-283.	5.7	98
76	Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities. <i>Pituitary</i> , 2017, 20, 46-62.	2.9	162
77	Pegvisomant in acromegaly: an update. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 577-589.	3.3	53
78	Adrenal Mass: Insight Into Pathogenesis and a Common Link With Insulin Resistance. <i>Endocrinology</i> , 2017, 158, 1527-1532.	2.8	13
79	Cardiovascular alterations in adult GH deficiency. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2017, 31, 25-34.	4.7	31
80	Association between vitamin D and sperm parameters: Clinical evidence. <i>Endocrine</i> , 2017, 58, 194-198.	2.3	32
81	Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib. <i>Endocrine</i> , 2017, 57, 539-543.	2.3	10
82	Acromegaly is associated with increased cancer risk: a survey in Italy. <i>Endocrine-Related Cancer</i> , 2017, 24, 495-504.	3.1	61
83	The environment and male reproduction: The effect of cadmium exposure on reproductive function and its implication in fertility. <i>Reproductive Toxicology</i> , 2017, 73, 105-127.	2.9	185
84	The role of vitamin D in male fertility: A focus on the testis. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017, 18, 285-305.	5.7	79
85	Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study. <i>Endocrine</i> , 2017, 56, 603-620.	2.3	14
86	Dopamine D2 receptor expression in the corticotroph cells of the human normal pituitary gland. <i>Endocrine</i> , 2017, 57, 314-325.	2.3	19
87	Six controversial issues on subclinical Cushing's syndrome. <i>Endocrine</i> , 2017, 56, 262-266.	2.3	37
88	Cardiovascular risk after cessation of growth hormone treatment in people born small for gestational age. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 930-932.	11.4	1
89	Serum IGF-1 is associated with cognitive functions in early, drug-naïve Parkinson's disease. <i>PLoS ONE</i> , 2017, 12, e0186508.	2.5	30
90	Influence of Bisphenol A on Type 2 Diabetes Mellitus. <i>International Journal of Environmental Research and Public Health</i> , 2016, 13, 989.	2.6	72

#	ARTICLE	IF	CITATIONS
91	Investigation of sperm telomere length as a potential marker of paternal genome integrity and semen quality. <i>Reproductive BioMedicine Online</i> , 2016, 33, 404-411.	2.4	65
92	Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease: 12-month, Phase III pasireotide study. <i>Endocrine</i> , 2016, 54, 516-523.	2.3	24
93	Metabolic Alterations and Cardiovascular Outcomes of Cortisol Excess. <i>Frontiers of Hormone Research</i> , 2016, 46, 54-65.	1.0	31
94	Comment on Azmahani et al. "Steroidogenic enzymes, their related transcription factors and nuclear receptors in human sebaceous glands under normal and pathological conditions". <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016, 155, 177.	2.5	0
95	Complications of Cushing's syndrome: state of the art. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 611-629.	11.4	371
96	Is mortality in Cushing's disease reversible with remission?. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 551-552.	11.4	2
97	Osilodrostat, a potent oral 11 β -hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease. <i>Pituitary</i> , 2016, 19, 138-148.	2.9	116
98	The effect of FT500 Plus \AA° on ovarian stimulation in PCOS women. <i>Reproductive Toxicology</i> , 2016, 59, 40-44.	2.9	20
99	Reduced bone mineral density in glycogen storage disease type III: evidence for a possible connection between metabolic imbalance and bone homeostasis. <i>Bone</i> , 2016, 86, 79-85.	2.9	23
100	The safety of treatments for prolactinomas. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 503-512.	2.4	19
101	The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 9718-9731.	1.8	19
102	Erectile Dysfunction Is Common among Men with Acromegaly and Is Associated with Morbidities Related to the Disease. <i>Journal of Sexual Medicine</i> , 2015, 12, 1184-1193.	0.6	23
103	Glycogen storage disease type Ia (GSDIa) but not Glycogen storage disease type Ib (GSDIb) is associated to an increased risk of metabolic syndrome: possible role of microsomal glucose 6-phosphate accumulation. <i>Orphanet Journal of Rare Diseases</i> , 2015, 10, 91.	2.7	21
104	Neuropsychiatric disorders in Cushing's syndrome. <i>Frontiers in Neuroscience</i> , 2015, 9, 129.	2.8	124
105	Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial. <i>Pituitary</i> , 2015, 18, 604-612.	2.9	46
106	The Treatment of Cushing's Disease. <i>Endocrine Reviews</i> , 2015, 36, 385-486.	20.1	353
107	Adverse events associated with somatostatin analogs in acromegaly. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1213-1226.	2.4	36
108	The treatment with pasireotide in Cushing's disease: effects of long-term treatment on tumor mass in the experience of a single center. <i>Endocrine</i> , 2015, 50, 725-740.	2.3	40

#	ARTICLE	IF	CITATIONS
109	The hypertension of Cushing's syndrome. <i>Journal of Hypertension</i> , 2015, 33, 44-60.	0.5	125
110	Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors. <i>Endocrine-Related Cancer</i> , 2014, 21, 601-613.	3.1	25
111	Is diabetes in Cushing's syndrome only a consequence of hypercortisolism?. <i>European Journal of Endocrinology</i> , 2014, 170, 311-319.	3.7	60
112	Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline. <i>Journal of Endocrinological Investigation</i> , 2014, 37, 1017-1030.	3.3	45
113	Could different treatment approaches in acromegaly influence life expectancy? A comparative study between Bulgaria and Campania (Italy). <i>European Journal of Endocrinology</i> , 2014, 171, 263-273.	3.7	32
114	Impaired Bone Metabolism in Glycogen Storage Disease Type 1 Is Associated with Poor Metabolic Control in Type 1a and with Granulocyte Colony-Stimulating Factor Therapy in Type 1b. <i>Hormone Research in Paediatrics</i> , 2014, 81, 55-62.	1.8	17
115	How should patients with adrenal incidentalomas be followed up?. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 352-354.	11.4	2
116	Molecular basis of pharmacological therapy in Cushing's disease. <i>Endocrine</i> , 2014, 46, 181-198.	2.3	27
117	Pituitary tumors and pregnancy: the interplay between a pathologic condition and a physiologic status. <i>Journal of Endocrinological Investigation</i> , 2014, 37, 99-112.	3.3	34
118	LCI699, a Potent 11 β -hydroxylase Inhibitor, Normalizes Urinary Cortisol in Patients With Cushing's Disease: Results From a Multicenter, Proof-of-Concept Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 1375-1383.	3.6	160
119	Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?. <i>Osteoporosis International</i> , 2014, 25, 441-446.	3.1	49
120	A novel heterozygous SOX2 mutation causing congenital bilateral anophthalmia, hypogonadotropic hypogonadism and growth hormone deficiency. <i>Gene</i> , 2014, 534, 282-285.	2.2	25
121	Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study. <i>Clinical Endocrinology</i> , 2014, 81, 408-417.	2.4	95
122	Cushing, acromegaly, GH deficiency and tendons. <i>Muscles, Ligaments and Tendons Journal</i> , 2014, 4, 329-32.	0.3	8
123	Investigational therapies for acromegaly. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 955-963.	4.1	13
124	Preoperative workup in the assessment of adrenal incidentalomas: outcome from 282 consecutive laparoscopic adrenalectomies. <i>BMC Surgery</i> , 2013, 13, 57.	1.3	28
125	Pasireotide for the treatment of Cushing's disease. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 557-567.	0.8	2
126	The Metabolic Profile in Active Acromegaly is Gender-Specific. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E51-E59.	3.6	54

#	ARTICLE	IF	CITATIONS
127	Results of a Single-Center Observational 10-Year Survey Study on Recurrence of Hyperprolactinemia after Pregnancy and Lactation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 372-379.	3.6	89
128	Treatment with GH receptor antagonist in acromegaly: effect on cardiac arrhythmias. <i>European Journal of Endocrinology</i> , 2013, 168, 15-22.	3.7	29
129	Endocrine changes (beyond diabetes) after bariatric surgery in adult life. <i>Journal of Endocrinological Investigation</i> , 2013, 36, 267-79.	3.3	6
130	Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study. <i>Pituitary</i> , 2012, 15, 539-551.	2.9	34
131	Growth hormone, prolactin, and sexuality. <i>Journal of Endocrinological Investigation</i> , 2012, 35, 782-794.	3.3	62
132	Subclinical Cushingâ€™s syndrome. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2012, 26, 497-505.	4.7	55
133	Predictors of morbidity and mortality in acromegaly: an Italian survey. <i>European Journal of Endocrinology</i> , 2012, 167, 189-198.	3.7	189
134	Pregnancy in acromegaly: experience from two referral centers and systematic review of the literature. <i>Clinical Endocrinology</i> , 2012, 76, 264-271.	2.4	64
135	Glycometabolic control in acromegalic patients with diabetes: a study of the effects of different treatments for growth hormone excess and for hyperglycemia. <i>Journal of Endocrinological Investigation</i> , 2012, 35, 154-9.	3.3	16
136	Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study. <i>European Journal of Endocrinology</i> , 2011, 165, 713-721.	3.7	69
137	Resistance to Somatostatin Analogs in Acromegaly. <i>Endocrine Reviews</i> , 2011, 32, 247-271.	20.1	220
138	Pathophysiology of Diabetes Mellitus in Cushingâ€™s Syndrome. <i>Neuroendocrinology</i> , 2010, 92, 77-81.	2.5	146
139	The treatment with growth hormone receptor antagonist in acromegaly: Effect on vascular structure and function in patients resistant to somatostatin analogues. <i>Journal of Endocrinological Investigation</i> , 2010, 33, 663-670.	3.3	34
140	Cardiovascular Disease in Cushingâ€™s Syndrome: Heart versus Vasculature. <i>Neuroendocrinology</i> , 2010, 92, 50-54.	2.5	86
141	Somatostatin Analogues: Treatment of Pituitary and Neuroendocrine Tumors. <i>Progress in Brain Research</i> , 2010, 182, 281-294.	1.4	28
142	Medical Treatment of Cushingâ€™s Disease with Pasireotide. <i>European Endocrinology</i> , 2010, 8, 99.	1.5	5
143	Glucose Tolerance and Somatostatin Analog Treatment in Acromegaly: A 12-Month Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2907-2914.	3.6	52
144	Impact of Somatostatin Analogs Versus Surgery on Glucose Metabolism in Acromegaly: Results of a 5-Year Observational, Open, Prospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 528-537.	3.6	51

#	ARTICLE	IF	CITATIONS
145	Effects of Initial Therapy for Five Years with Somatostatin Analogs for Acromegaly on Growth Hormone and Insulin-Like Growth Factor-I Levels, Tumor Shrinkage, and Cardiovascular Disease: A Prospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3746-3756.	3.6	132
146	Significant tumour shrinkage after 12 months of lanreotide Autogel 120µg treatment given first-line in acromegaly. <i>Clinical Endocrinology</i> , 2009, 71, 237-245.	2.4	64
147	Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing's syndrome. <i>Journal of Endocrinological Investigation</i> , 2009, 32, 390-394.	3.3	25
148	The Medical Treatment of Cushing's Disease: Effectiveness of Chronic Treatment with the Dopamine Agonist Cabergoline in Patients Unsuccessfully Treated by Surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 223-230.	3.6	297
149	The accuracy of the arginine growth hormone test in Parkinsonism. <i>Movement Disorders</i> , 2008, 23, 1331-1331.	3.9	0
150	Cushing's Syndrome. <i>Endocrinology and Metabolism Clinics of North America</i> , 2008, 37, 135-149.	3.2	166
151	Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire. <i>European Journal of Endocrinology</i> , 2008, 158, 623-630.	3.7	193
152	Impact of Treating Acromegaly First with Surgery or Somatostatin Analogs on Cardiomyopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 2639-2646.	3.6	78
153	Correlation of in Vitro and in Vivo Somatotrophic Adenoma Responsiveness to Somatostatin Analogs and Dopamine Agonists with Immunohistochemical Evaluation of Somatostatin and Dopamine Receptors and Electron Microscopy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 1412-1417.	3.6	114
154	Effects of sex steroids on bone in women with subclinical or overt endogenous hypercortisolism. <i>European Journal of Endocrinology</i> , 2007, 157, 359-366.	3.7	65
155	Dopamine Receptor Expression and Function in Corticotroph Ectopic Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 65-69.	3.6	67
156	Treatment with Growth Hormone Receptor Antagonist in Acromegaly: Effect on Cardiac Structure and Performance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 476-482.	3.6	74
157	Beneficial effect of dose escalation of Octreotide-LAR as first-line therapy in patients with acromegaly. <i>European Journal of Endocrinology</i> , 2007, 157, 579-587.	3.7	77
158	A retrospective analysis on biochemical parameters, cardiovascular risk and cardiomyopathy in elderly acromegalic patients. <i>Journal of Endocrinological Investigation</i> , 2007, 30, 497-506.	3.3	20
159	Cushing's syndrome: aftermath of the cure. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2007, 51, 1381-1391.	1.3	73
160	Novel insights in dopamine receptor physiology. <i>European Journal of Endocrinology</i> , 2007, 156, S13-S21.	3.7	114
161	Bone Demineralization and Vertebral Fractures in Endogenous Cortisol Excess: Role of Disease Etiology and Gonadal Status. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 1779-1784.	3.6	126
162	Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. <i>European Journal of Endocrinology</i> , 2006, 154, 467-477.	3.7	148

#	ARTICLE	IF	CITATIONS
163	Cabergoline plus Lanreotide for Ectopic Cushing's Syndrome. <i>New England Journal of Medicine</i> , 2005, 352, 2457-2458.	27.0	78
164	Sulfur Amino Acids in Cushing's Disease: Insight in Homocysteine and Taurine Levels in Patients with Active and Cured Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 6616-6622.	3.6	33
165	The Metabolic Syndrome and Cardiovascular Risk in Cushing's Syndrome. <i>Endocrinology and Metabolism Clinics of North America</i> , 2005, 34, 327-339.	3.2	146
166	Dopamine Receptor Expression and Function in Human Normal Adrenal Gland and Adrenal Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 4493-4502.	3.6	70
167	Dopamine Receptor Expression and Function in Corticotroph Pituitary Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2452-2462.	3.6	246
168	Dopamine Receptor Expression and Function in Clinically Nonfunctioning Pituitary Tumors: Comparison with the Effectiveness of Cabergoline Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 1674-1683.	3.6	120
169	Cardiac Abnormalities in Acromegaly. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2004, 3, 309-318.	1.8	32
170	Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. <i>Clinical Endocrinology</i> , 2003, 58, 169-176.	2.4	99
171	Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study. <i>Clinical Endocrinology</i> , 2003, 58, 302-308.	2.4	99
172	High Prevalence of Cardiac Valve Disease in Acromegaly: An Observational, Analytical, Case-Control Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 3196-3201.	3.6	119
173	Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. <i>European Journal of Endocrinology</i> , 2003, 148, 325-331.	3.7	203
174	Nephrolithiasis in Cushing's Disease: Prevalence, Etiopathogenesis, and Modification after Disease Cure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2076-2080.	3.6	91
175	Central Diabetes Insipidus and Autoimmunity: Relationship between the Occurrence of Antibodies to Arginine Vasopressin-Secreting Cells and Clinical, Immunological, and Radiological Features in a Large Cohort of Patients with Central Diabetes Insipidus of Known and Unknown Etiology. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 1629-1636.	3.6	109
176	Cardiovascular Risk Factors and Common Carotid Artery Caliber and Stiffness in Patients with Cushing's Disease during Active Disease and 1 Year after Disease Remission. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2527-2533.	3.6	314
177	Role of somatostatin analogs in the management of non-functioning neuroendocrine tumors. <i>Journal of Endocrinological Investigation</i> , 2003, 26, 82-8.	3.3	16
178	Dopamine receptor agonists for treating prolactinomas. <i>Expert Opinion on Investigational Drugs</i> , 2002, 11, 787-800.	4.1	112
179	Short-Term Suppression of GH and IGF-I Levels Improves Gonadal Function and Sperm Parameters in Men with Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 4193-4197.	3.6	37
180	Early Vascular Alterations in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3174-3179.	3.6	100

#	ARTICLE	IF	CITATIONS
181	The Cardiovascular Risk of Adult GH Deficiency (GHD) Improved after GH Replacement and Worsened in Untreated GHD: A 12-Month Prospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 1088-1093.	3.6	99
182	Cardiovascular Consequences of Early-Onset Growth Hormone Excess. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3097-3104.	3.6	82
183	Hypothalamus-pituitary-adrenal axis in central diabetes insipidus: ACTH and cortisol responsiveness to CRH administration. <i>Journal of Endocrinological Investigation</i> , 2002, 25, 932-937.	3.3	6
184	Severe impairment of bone mass and turnover in Cushing's disease: comparison between childhood-onset and adulthood-onset disease. <i>Clinical Endocrinology</i> , 2002, 56, 153-158.	2.4	67
185	Early Vascular Alterations in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3174-3179.	3.6	20
186	Central diabetes insipidus and heart: effect of acute arginine vasopressin deficiency and replacement treatment with desmopressin on cardiac performance. <i>Clinical Endocrinology</i> , 2001, 54, 97-106.	2.4	7
187	Increased arterial intima-media thickness by B-mode echodoppler ultrasonography in acromegaly. <i>Clinical Endocrinology</i> , 2001, 54, 515-524.	2.4	101
188	Cardiovascular complications in acromegaly: methods of assessment. <i>Pituitary</i> , 2001, 4, 251-257.	2.9	25
189	Spine abnormalities and damage in patients cured from Cushing's disease. <i>Pituitary</i> , 2001, 4, 153-161.	2.9	31
190	Uncommon clinical course of multiple osteochondromatosis in a patient with a long-term history of Cushing's disease. <i>Pituitary</i> , 2001, 4, 187-193.	2.9	1
191	Resistance to Cabergoline as Compared with Bromocriptine in Hyperprolactinemia: Prevalence, Clinical Definition, and Therapeutic Strategy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 5256-5261.	3.6	200
192	Is the Acromegalic Cardiomyopathy Reversible? Effect of 5-Year Normalization of Growth Hormone and Insulin-Like Growth Factor I Levels on Cardiac Performance*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1551-1557.	3.6	102
193	Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. <i>Clinical Endocrinology</i> , 2000, 52, 319-327.	2.4	91
194	Does the age of onset of growth hormone deficiency affect cardiac performance? A radionuclide angiography study. <i>Clinical Endocrinology</i> , 2000, 52, 447-455.	2.4	39
195	The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. <i>Clinical Endocrinology</i> , 2000, 53, 53-60.	2.4	77
196	Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease. <i>Clinical Endocrinology</i> , 2000, 53, 13-19.	2.4	52
197	Macroprolactinoma Shrinkage during Cabergoline Treatment Is Greater in Naive Patients Than in Patients Pretreated with Other Dopamine Agonists: A Prospective Study in 110 Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 2247-2252.	3.6	172
198	Bone Loss Is Correlated to the Severity of Growth Hormone Deficiency in Adult Patients with Hypopituitarism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 1919-1924.	3.6	166

#	ARTICLE	IF	CITATIONS
199	Persistence of Increased Cardiovascular Risk in Patients with Cushing's Disease after Five Years of Successful Cure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 2664-2672.	3.6	344
200	Effect of a Short-Term Treatment with Alendronate on Bone Density and Bone Markers in Patients with Central Diabetes Insipidus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 2349-2352.	3.6	14
201	The Growth Hormone (GH) Response to the Arginine Plus GH-Releasing Hormone Test Is Correlated to the Severity of Lipid Profile Abnormalities in Adult Patients with GH Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 1277-1282.	3.6	93
202	Effect of Growth Hormone (GH) and Insulin-Like Growth Factor I on Prostate Diseases: An Ultrasonographic and Endocrine Study in Acromegaly, GH Deficiency, and Healthy Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 1986-1991.	3.6	67
203	Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. <i>Pituitary</i> , 1999, 1, 115-120.	2.9	81
204	Complete remission of Nelson's syndrome after 1-year treatment with cabergoline. <i>Journal of Endocrinological Investigation</i> , 1999, 22, 860-865.	3.3	63
205	The Growth Hormone (GH) Response to the Arginine Plus GH-Releasing Hormone Test Is Correlated to the Severity of Lipid Profile Abnormalities in Adult Patients with GH Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 1277-1282.	3.6	25
206	Effect of Growth Hormone (GH) and Insulin-Like Growth Factor I on Prostate Diseases: An Ultrasonographic and Endocrine Study in Acromegaly, GH Deficiency, and Healthy Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 1986-1991.	3.6	23
207	Effect of a Short-Term Treatment with Alendronate on Bone Density and Bone Markers in Patients with Central Diabetes Insipidus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 2349-2352.	3.6	5
208	Effect of corticotrophin-releasing hormone on arginine vasopressin and atrial natriuretic factor in patients with Cushing's disease. <i>Clinical Endocrinology</i> , 1998, 49, 77-84.	2.4	13
209	Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease. <i>Clinical Endocrinology</i> , 1998, 48, 655-662.	2.4	78
210	Impairment of Bone Status in Patients with Central Diabetes Insipidus*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2275-2280.	3.6	24
211	Bone Marker and Bone Density Responses to Dopamine Agonist Therapy in Hyperprolactinemic Males. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 807-813.	3.6	33
212	Long-Term and Low-Dose Treatment with Cabergoline Induces Macroprolactinoma Shrinkage. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 3574-3579.	3.6	146
213	Identification of vitamin D (VDR) and retinoic X (RXR) receptor in normal and neoplastic human reproductive tissues. <i>Endocrine Abstracts</i> , 0, , .	0.0	2
214	Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. <i>Endocrine Abstracts</i> , 0, , .	0.0	2